Trial reportNature medicine2026
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.
Trial report in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and Safety of Bimagrumab in Adults With Obesity and Metabolic Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Diabetes, obesity & metabolism · 2026Pooled it
- Association of sarcopenia and muscle attenuation with clinical outcomes in patients with diabetic foot: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Cardiac safety of chronic inhibition of the myostatin-activin pathway with bimagrumab in healthy older adults.The Journal of clinical endocrinology and metabolism · 2026Trial
- Review
- Adipose Tissue Remodeling Beyond Weight Loss: New Insights Into Incretin-Based Therapies and Bariatric Surgery.Current obesity reports · 2026Review
- Exerkine-Mediated Inter-Organ Crosstalk and Translational Perspectives in Metabolic Diseases.Current obesity reports · 2026Review
- Strengthening the metabolic alliance: exercise as an essential partner of obesity pharmacotherapy.Nature reviews. Endocrinology · 2026Article
- Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies.Diabetes & metabolism journal · 2026Review
- The hallmarks of skeletal muscle health.Nature metabolism · 2026Review
- Combination Pharmacotherapies for Obesity-Current Evidence and Future Directions.Endocrinology, diabetes & metabolism · 2026Review
- Emerging Myostatin and Metabolic Hormone Pathway Modulators in Cardiometabolic Disease: Mechanisms, Evidence, and Therapeutic Potential.Journal of cardiovascular translational research · 2026Review
- Age-Dependent Effect of Myostatin Blockade in theMuscles (Basel, Switzerland) · 2026Article
- Beyond One-Size-Fits-All: Individually Tailored Dietary Interventions in Modern Obesity Care.Nutrients · 2026Review
- Review
- Semaglutide-induced loss of skeletal muscle mass is blunted by co-administration of ketone esters.JCI insight · 2026Article
- Beyond weight loss: Preserving muscle health in the incretin era.Journal of diabetes investigation · 2026Article
- Weight regain after obesity treatment: mechanisms, predictors, and real-world evidence from the IGOBE program.Reviews in endocrine & metabolic disorders · 2026Review
- Sleep and obesity-known interactions and open questions.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026Review
- The evolving landscape of obesity pharmacotherapy.Nature reviews. Drug discovery · 2026Review
- Integrating metabolic rehabilitation with incretin-based anti-obesity therapy: a narrative review of a multimodal strategy for sustainable weight loss.International journal of obesity (2005) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Bimagrumab is an investigational antibody targeting type II activin receptors, intended to reduce total body and visceral fat mass and promote muscle growth. In this double-blind, placebo-controlled phase 2, trial, 507 adults with obesity (body mass index ≥30 kg m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.